Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3399-3407

  Edwards, Robert P ^a   Gooding, William ^a   Lembersky, Barry C ^a   Colonello, Kelly ^a   Hammond, Rose ^a   Paradise, Carolyn ^a   Kowal, Charles D ^a   Kunschner, Alan J ^a   Baldisseri, Maria ^a   Kirkwood, John M ^a   Herberman, Ronald B ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTESTINE PERFORATION; INTRAPERITONEAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 9844256432     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3399     Document Type: Article

References (28)

1. Cancer Facts and Figures - 1995. Atlanta, GA, American Cancer Society, 1995
2. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
3. Thigpen JT, Vance RB, Khansur T: Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71:1559-1564, 1992
4. Markman M, Blessing J, Major F, et al: Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: A Gynecologic Oncology Group study. Gynecol Oncol 50:191-195, 1993
5. Markman M, Riechman B, Hakes T, et al: Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10:1479-1484, 1992
6. Walpole ET, Dutcher JP, Sparano J, et al: Survival after phase 11 treatment of advanced renal cell carcinoma with Taxol or high dose interleukin-2. J Immunother 13:275-281, 1993
7. Lotze MT, Rosenberg SA: Interleukin-2: Clinical applications, in DeVita VT, Hellman S, Rosenberg S (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 159-177
8. Gillis S, Ferm MM, Ou W, et al: T cell growth factor: Parameters of production and a quantitative microassay for activity. J Immunol 120:2027-2032, 1978
9. Collett D: Modelling Survival Data in Medical Research. New York, NY, Chapman & Hall, 1994
10. Westfall P, Young S: Resampling Based Multiple Testing. New York, NY, Wiley, 1993
11. National Cancer Institute Statement: Ovarian Cancer: Screening, Treatment, and Followup. Apr 5-7:1-303, 1994
12. Copeland L, Gershenson D, Taylor Wharton J, et al: Microscopic disease at second-look laparotomy in advanced ovarian cancer. Cancer 55:472-478, 1985
13. Neijt J, Huinink W, VanderBurg M, et al: Complete remission at laparotomy: Still a gold standard in ovarian cancer. Lancet 1:1028, 1986
14. Potter ME, Hatch KD, Soong S-J, et al: Second-look laparotomy and salvage therapy: A research modality only? Gynecol Oncol 44:3-9, 1992
15. Luesley D, Lawton F, Blackledge G, et al: Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 2:599-603, 1988
16. Lentz SS, McKean DJ, Kovach JS, et al: Phenotypic and functional characteristics of mononuclear cells in ovarian carcinoma tumors. Gynecol Oncol 34:136-140, 1989
17. Mizoguchi H, O'Shea JJ, Longo DL, et al: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1797, 1992
18. Lai P, Rabinowich H, Crowley-Nowick P, et al: Alteration in expression and function of signal-tranducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2:161-173, 1996
19. Ioannides CG, Fisk B, Fan D, et al: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu protooncogene. Cell Immunol 151:225-234, 1993
20. Peoples G, Yoshino I, Douville C, et al: TCR Vb 3+ and Vb 6+ CTL recognized tumor-associated antigens related to HER2/ neu expression in HLA-A2+ ovarian cancers. J Immunol 152:4993-4999, 1994
21. Steis RG, Urba WJ, VanderMolen LA, et al: Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 8:1618-1629, 1990
22. Lembersky B, Baldisseri M, Kunschner A, et al: Phase I-II study of intraperitoneal low dose interleukin-2 in refractory stage III ovarian cancer. Proc Am Soc Clin Oncol 8:163, 1989 (abstr 636)
23. de Dycker RP, Neumann RLA, Schumacher T, et al: Sequential Proleukin (rIL-2) by continuous infusion with cisplatin and cyclophosphamide in patients with unresectable ovarian cancer. Eur J Cancer 27:804, 1991
24. Berek JS, Hacker NF, Liechtenstein A, et al: Intraperitoneal recombinant α-interferon for salvage immunotherapy in stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Cancer Res 45:4447-4453, 1985
25. Pujade-Louraine E, Guastalla JP, Colombo N, et al: Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14:343-350, 1996
26. Vlasveld LT, Rodenhuis S, Rutgers EJ, et al: Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter. Eur J Surg One 20:122-129, 1994
27. Guastalla JP, Vermorken JB, Wils JA, et al: Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advance ovarian carcinoma patients with minimal residual disease. Eur J Cancer 30A:45-49, 1994
28. Markman M, Rowinsky E, Hakes T, et al: Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group Study. J Clin Oncol 10:1485-1491, 1992